Stocks of Esperion Therapeutics Inc (NASDAQ:ESPR) traded higher last session on Wall Street, down -5.45% to $2.08.
ESPR stock price is now -15.42% away from the 50-day moving average and -5.98% away from the 200-day moving average. The market capitalization of the company currently stands at $409.84M.
With the price target of $4, Goldman recently initiated with Neutral rating for Esperion Therapeutics Inc (NASDAQ: ESPR). On December 17, 2024, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $8, while ‘BofA Securities’ rates the stock as ‘Underperform’
In other news, Halladay Benjamin, Chief Financial Officer sold 9 shares of the company’s stock on Jan 17 ’25. The stock was sold for $20 at an average price of $2.27. Upon completion of the transaction, the Chief Financial Officer now directly owns 240,682 shares in the company, valued at $0.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17 ’25, Chief Commercial Officer Warren Eric sold 123 shares of the business’s stock. A total of $278 was realized by selling the stock at an average price of $2.26. This leaves the insider owning 159,998 shares of the company worth $0.33 million. A total of 0.99% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc has had a low of $1.58 and a high of $3.94. The fifty day moving average price for ESPR is $2.4598 and a two-hundred day moving average price translates $2.218 for the stock.
The latest earnings results from Esperion Therapeutics Inc (NASDAQ: ESPR) was released for 2024-09-30. The company reported revenue of $51.63 million for the quarter, compared to $33.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 52.0 percent. For the current quarter, analysts expect ESPR to generate $64.26M in revenue.
